Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bepridil: a new long-acting calcium channel blocking agent.

F P Zeller, S A Spinler

    Drug Intelligence & Clinical Pharmacy
    |June 1, 1987
    PubMed
    Summary

    Bepridil, a calcium channel blocker, demonstrates antianginal efficacy by improving myocardial oxygen supply and demand. Its complex profile includes antiarrhythmic properties and good tolerance, supporting its potential use in angina treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The skinny on treatment of venous thromboembolism in obesity.

    Journal of thrombosis and haemostasis : JTH·2005
    Same author

    Antithrombotic agents for secondary prevention of cardioembolic and noncardioembolic stroke--another viewpoint.

    Pharmacotherapy·2001
    Same author

    Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.

    Pharmacotherapy·2001
    Same author

    Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.

    The Annals of pharmacotherapy·2001
    Same author

    Update on strategies to improve thrombolysis for acute myocardial infarction.

    Pharmacotherapy·2001
    Same author

    New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.

    The Annals of pharmacotherapy·2001

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Bepridil is an investigational calcium channel blocking agent.
    • It possesses a unique and complex pharmacologic profile with antianginal activity.

    Purpose of the Study:

    • To evaluate the antianginal efficacy and safety of bepridil.
    • To explore its electrophysiologic and hemodynamic effects.

    Main Methods:

    • Clinical trials were conducted in the U.S. to assess short-term and long-term efficacy.
    • Pharmacologic and electrophysiologic properties were analyzed.

    Main Results:

    • Bepridil demonstrated significant improvement in subjective and objective antianginal parameters without depressing left ventricular function.
    • Long-term use showed sustained antianginal effects.
    • The drug exhibits Class I, III, and IV antiarrhythmic activity.
    • Common side effects include diarrhea and dizziness; tolerance was excellent.

    Conclusions:

    • Bepridil favorably modifies myocardial oxygen supply and demand, supporting its role as an antianginal drug.
    • Its long half-life allows for once-daily dosing, a significant advantage.
    • Further research is needed for its use in acute myocardial infarction and arrhythmias.

    Related Experiment Videos